Great Point Partners is a Greenwich, Connecticut based private investment firm focused on the healthcare industry. The acquisition is the latest in a series of CDMO investments: which include Cytovance Biologics, MaSTherCell, Tergus Pharma and Bionova Scientific.
Cellipont Bioservices is based in San Diego, California with more than 15 years of experience in the development and small-to-large batch manufacturing of cell therapies: championing its ability to productively grow challenging cells.
The company’s board of directors has appointed Deborah Wild as President and Chief Executive Officer and Will James as Chief Financial Officer. Carolyn Wrightson, who has served as Chief Operating Officer for the predecessor company for more than 15 years, will continue in that role.
“As we shift into the next chapter of the company’s existence, we felt rebranding was important to reflect the essence of our team and mission,” said CEO Deborah Wild. “By combining “cell” with the latin root for bridge (pont), the name Cellipont Bioservices reflects several dimensions of our vision: we bridge our innovator clients with patients; we bridge technical excellence and personal service; and for our team, we bridge personal passion with professional vocation. We are excited to reintroduce Cellipont Bioservices to the industry over the coming months.”